$901 Million is the total value of GREAT POINT PARTNERS LLC's 31 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 70.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS, INC. | $128,995,000,000 | +243539.6% | 5,260,803 | -5.5% | 14.32% | +173.3% |
| ACAD | Sell | ACADIA PHARMACEUTICALS, INC. | $40,095,000,000 | +74564.8% | 1,500,000 | -25.0% | 4.45% | -16.3% |
| GNFT | Sell | GENFITads | $13,711,000,000 | +46333.9% | 694,253 | -43.6% | 1.52% | -47.9% |
| MNLO | Sell | MENLO THERAPEUTICS INC. | $10,386,000,000 | +64217.6% | 1,733,882 | -15.7% | 1.15% | -27.8% |
| FOMX | Sell | FOAMIX PHARMACEUTICALS LTD | $5,022,000,000 | +49553.9% | 2,110,071 | -21.8% | 0.56% | -44.3% |
| OSMT | Sell | OSMOTICA PHARMACEUTICALS PLC | $3,522,000,000 | +65122.2% | 926,933 | -38.2% | 0.39% | -26.8% |
| FPRX | Sell | FIVE PRIME THERAPEUTICS, INC. | $3,303,000,000 | +10177.2% | 547,712 | -77.2% | 0.37% | -88.5% |
| ZFGN | Sell | ZAFGEN INC. | $2,631,000,000 | +30765.8% | 2,211,194 | -28.9% | 0.29% | -65.4% |
| AKBA | Exit | AKEBIA THERAPEUTICS INC | $0 | – | -131,531 | -100.0% | -0.11% | – |
| NVAX | Exit | NOVAVAX INCput | $0 | – | -2,000,000 | -100.0% | -0.11% | – |
| SLDB | Exit | SOLID BIOSCIENCES INCcall | $0 | – | -200,000 | -100.0% | -0.18% | – |
| NVAX | Exit | NOVAVAX INCcall | $0 | – | -4,500,000 | -100.0% | -0.24% | – |
| SVRA | Exit | SAVARA INC | $0 | – | -660,366 | -100.0% | -0.48% | – |
| ARRY | Exit | ARRAY BIOPHARMA INCcall | $0 | – | -200,000 | -100.0% | -0.48% | – |
| DERM | Exit | DERMIRA INCput | $0 | – | -555,300 | -100.0% | -0.74% | – |
| CTMX | Exit | CYTOMX THERAPEUTICS INC | $0 | – | -959,077 | -100.0% | -1.02% | – |
| FGEN | Exit | FIBROGEN INCput | $0 | – | -200,000 | -100.0% | -1.08% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -998,841 | -100.0% | -1.31% | – |
| KRYS | Exit | KRYSTAL BIOTECH INC | $0 | – | -492,100 | -100.0% | -1.60% | – |
| ASND | Exit | ASCENDIS PHARMA ASput | $0 | – | -200,000 | -100.0% | -2.33% | – |
| EPZM | Exit | EPIZYME INC | $0 | – | -2,173,913 | -100.0% | -2.67% | – |
| PBYI | Exit | PUMA BIOTECHNOLOGY INC | $0 | – | -900,000 | -100.0% | -3.46% | – |
| ARRY | Exit | ARRAY BIOPHARMA INC | $0 | – | -1,800,000 | -100.0% | -4.34% | – |
| UTHR | Exit | UNITED THERAPEUTICS CORP DEL | $0 | – | -379,832 | -100.0% | -4.41% | – |
| ICPT | Exit | INTERCEPT PHARMACEUTICALS INCput | $0 | – | -400,000 | -100.0% | -4.43% | – |
| BCRX | Exit | BIOCRYST PHARMACEUTICALS | $0 | – | -5,955,762 | -100.0% | -4.80% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS INC | $0 | – | -1,180,000 | -100.0% | -6.18% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.